Lastly, Ji et al. demonstrated that serum sclerostin levels increase gradually, along with renal deterioration in CKD stage 3–5 patients, and that sclerostin can be an independent risk factor for aortic valve calcification in this patient population [139]. Here, SOST is linked to chronic kidney disease.